top of page
Wide_PrimaryAlt3 Padding.png

Sisterhood Content brought to you by:

BBN_Biotech_Logo_rgb_high-3.jpg
SF Healthcare Week: Alnylam CEO Yvonne Greenstreet discusses the launch of Amvuttra in ATTR-CM and the company's new 2030 ambitions | 01/13/26

About the show: Members of the Biotech CEO Sisterhood regularly interview women leaders in biotech about news, science, management topics and more. Tune in to hear from top leaders in biotech about topics that matter to the industry.

Editorial Board Members

About the Sisterhood

The Biotech CEO Sisterhood is a vibrant community dedicated to championing the success of women leaders in the biopharma industry.  Rooted in a culture of mutual support and authenticity, the Sisterhood aims to inspire and uplift women while driving meaningful conversations and impact across the industry.  As part of our commitment to nurturing the current and future generations of biotech leaders, the Sisterhood hosts summits, local events, and educational sessions. These programs encourage dialogue about the challenges facing women in biotech, share best practices, and enhance leadership effectiveness.  Since its inception in 2022, the Biotech CEO Sisterhood has grown to 300+ members.  To follow our progress and learn more, please follow us on LinkedIn.

  • LinkedIn
Abigail-Jenkins.jpg.webp

Abigail Jenkins

Erika Smith.jpg

Erika Smith

Grace Colón headshot.jpg

Grace Colón

Julia Owens Headshot.png

Julia Owens

LUBA_GREENWOOD High Res.jpg

Luba Greenwood

Sheila-IMG_0248-Full Size-Glow cropped.jpg

Sheila Gujrathi

Episodes

BIO 2026: Vir's is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here | 06/24/26
Recludix will have initial clinical data for its SH2 STAT6 soon (2H 2026) - while it already made waves via a big partnership, a positive clinical profile could signal that SH2's time has arrived | 06/26/26
BIO 2026: Texas based Nanoscope Therapeutics is using optogenetics, or light to turn cells on or off, to try to restore vision for retinal conditions | 06/26/26
BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space | 06/25/26
BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes | 06/24/26
EHA 2026: Caribou Biosciences CEO Rachel Haurwitz shares an EHA update on her company's CD19 and BCMA allogeneic CAR-T programs | 06/12/26
ASCO 2026: Vir Biotechnology CEO Marianne De Backer discusses the company's masked T-cell engager platform, which recently earned the company a partnership with Astellas on PSMA | 05/30/26
ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck | 05/31/26
ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors | 05/13/26
ASGCT 2026: Siren Biotechnology recently has seen two INDs cleared for its AAV based gene therapy for oncology. Founder Nicole Paulk discusses how they are prepared to enter the clinic shortly | 05/13/26
SGCT 2026: Epicrispr Biotechnologies is already in the clinical with its epigenetic approach to genetic medicine. At ASGCT, it showed off how versatile this platform might be | 05/12/26
Barclays Miami: Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK | 03/10/26
Barclays Miami: Electra Therapeutics has taken a novel approach to target Signal Regulatory Proteins (SIRPs). It's in a pivotal for its first indication right now | 03/10/26
Ovid Therapeutics' new CEO Meg Alexander walks us through the company's lead programs in neurology | 02/02/26
Co-Founders Sheila Gujrathi and Julia Owens talk about the creation of the Biotech CEO Sisterhood and the new dimensions and next steps it is taking as an organization ahead | 02/02/26

01/14/26 - Sheila Gujrathi at JPM '26

01/14/26 - Julia Owens at JPM '26

01/14/26 - Elizabeth Tuck at JPM '26

Bluejay Therapeutics' CEO Keting Chu talks about what led to the the successful $620M+ acquisition of her company and its chronic hepatitis delta virus antibody by Mirum

01/14/26 - Abigail Jenkins at JPM '26

01/14/26 - Christine Ann Miller at JPM '26

01/14/26 - Shehnaaz Suliman

at JPM '26

SF Healthcare Week: CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year | 01/15/26
SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech
Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead | 01/13/26
Biotech CEO Sisterhood: Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further | 12/15/25
Biotech CEO Sisterhood: EpiBone creates bones and cartilage grown from stem cells - Co-Founder and CEO Nina Tandon describes the creative thinking she has used to accelerate its availability | 12/11/25
Biotech leader Sheila Gujrathi discusses her new book, The Mirror Effect, which she wrote for her younger self, today's peers, and the next generation of female leaders in business | 12/2/25
Biotech CEO Sisterhood: Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that lead to the first approved therapy for Barth Syndrome | 11/13/25
Biotech CEO Sisterhood: Hanadie Yousef leads Juvena Therapeutics, a company is developing protein based therapeutics that are tissue restorative for muscle and metabolic diseases | 09/04/25
Biotech CEO Sisterhood: Catherine Pickering is leading iOnctura, which is focused on solving the problem of cancer resistance both at the tumor and around its environment | 09/04/25
Biotech CEO Sisterhood: Sheila Gujrathi is an experienced leader in biotech, a co-founder of the Biotech CEO Sisterhood, and has a new book coming out next month | 09/04/25
Biotech CEO Sisterhood: Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance | 09/04/25
Biotech CEO Sisterhood: Catherine Sabatos-Peyton is running Larkspur Biosciences, a company targeting cancer cell fitness | 09/04/25
Biotech CEO Sisterhood: Kiran Mazumdar-Shaw, builder of India's leading biotech enterprise and a pioneer in the development of biologics and biosimilars, shares her story and learnings from business | 09/02/25
Biotech CEO Sisterhood: Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership | 08/19/25
Biotech CEO Sisterhood: Trevi Therapeutics' Co-Founder & CEO Jennifer Good on good communication and capital efficiency, and a unique internship program in life sciences | 08/06/25
Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and on leadership | 07/18/25
Biotech CEO Sisterhood: Daré Bioscience's Founder & CEO Sabrina Johnson describes her company's mission to make women's health a priority | 05/06/25
Biotech CEO Sisterhood: Named CEO of Acadia Pharmaceuticals in September, Catherine Owen Adams describes taking the leap from a career in 'pharma' to running an independent, commercial stage biotech | 04/22/25
Biotech CEO Sisterhood: X4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease space | 04/08/25
Biotech CEO Sisterhood: Gallop Oncology CEO Luba Greenwood on the importance of the Sisterhood, the Massachusetts life sciences ecosystem, and the work at Gallop | 03/27/25
Biotech CEO Sisterhood: Alnylam CEO Yvonne Greenstreet on her career path, the importance of diversity of opinions, and leading Alnlyam into a critical phase of growth | 03/17/25
Biotech CEO Sisterhood Vir's CEO Marianne De Backer describes her background and leadership style, and joining Vir as it experienced a road bump, but turning it into an opportunity via a key IO deal | 03/03/25
Biotech CEO Sisterhood: Serial entrepreneur Sheila Mikhail on overcoming obstacles and getting the job done, including multiple major buyouts in her own career | 02/18/25
Biotech CEO Sisterhood: Avidity Biosciences' CEO Sarah Boyce discusses a leader's responsibility to address dysfunction and the importance of corporate culture | 02/04/25
Biotech CEO Sisterhood: Mary Lynne Hedley shares advice on board makeup, running board meetings, and other factors into having an effective board of directors | 01/21/25
Biotech CEO Sisterhood: A leadership series discussion on building an effective board, best practices for running meetings, hiring talent, and decision making | 01/06/24
Biotech CEO Sisterhood: Heather Turner and Sheila Gujrathi discuss managing your board of directors effectively | 12/19/24
Biotech CEO Sisterhood: Melinta Therapeutics CEO Christine Miller on expanding the company into the acute care business, improving employee satisfaction, and her leadership principles | 12/12/24
Biotech veteran Deborah Dunsire on trends in drug development, investments, regulation, and her advice on key skills for growing into position of leadership | 12/5/24

The Sisterhood in their own words

Pink on the Square at JPM '26

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page